Discovery of benzimidazole substituted 1, 2, 4-oxadiazole compounds as novel anti-HBV agents with TLR8-agonistic activities
- 6 October 2022
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 244, 114833
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81703359)
- Natural Science Foundation of Jiangsu Province (BK20181151, BK20211056)
- Six Talent Peaks Project in Jiangsu Province (2017-YY-039)
- Xuzhou Municipal Science and Technology Bureau
- Xuzhou Science and Technology Program (KC21011)
This publication has 24 references indexed in Scilit:
- Benzimidazole: A Milestone in the Field of Medicinal ChemistryMini-Reviews in Medicinal Chemistry, 2020
- Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitorsEuropean Journal of Medicinal Chemistry, 2019
- Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonistsBioorganic & Medicinal Chemistry Letters, 2018
- Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effectorEuropean Journal of Medicinal Chemistry, 2017
- Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitorsEuropean Journal of Medicinal Chemistry, 2016
- Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B VirusJournal of Medicinal Chemistry, 2016
- Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral HepatitisJournal of Medicinal Chemistry, 2013
- Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic LigandsScience, 2013
- Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8The Journal of Immunology, 2005
- Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirusHepatology, 1998